A range of serological checks have been developed to detect the presence of antibodies against the extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated the efficiency of 18 commercially accessible SARS-CoV-2 antibody assays. Early (6-Eight days after the begin of signs) and late sera (>14 days) from ICU sufferers (n=10 and n=16, respectively) and healthcare employees (n=5 and n=9, respectively) have been included. Additionally, 22 sera have been included to detect potential cross-reactivity. Test traits have been decided for the 18 assays. In >14 days samples, the Vircell IgG and Wantai Ig ELISAs had superior sensitivity in comparison with the different ELISAs (96%).
Furthermore, the Roche Ig, the Epitope Diagnostics IgM, Wantai IgM, Euroimmun IgG, and IgA all confirmed a specificity of 100%. The POCTs of Boson Biotech and ACRO Biotech confirmed the highest sensitivities: 100% and 96% (83.5-99.8), respectively. The POCT of Orient Gene Biotech, VOMED Diagnostics, and Coris-Bioconcept confirmed highest specificities (100%). For the IgM and IgA assays, the Euroimmun IgA take a look at confirmed the highest sensitivity in early samples: 46.7% (23.5-70.9) to 53.3% (29.1-76.5). In basic, all checks carried out higher in sufferers with extreme signs (ICU sufferers). We conclude that the Wantai Ig and Vircell IgG ELISAs could also be appropriate for diagnostic functions.
The IgM/IgA checks carried out poorer than their IgG/Ig counterparts however could have a task in diagnoses of SARS-CoV-2 in a inhabitants in which the background seroprevalence of IgG excessive, and IgM and/or IgA could distinguish between acute or previous an infection. The o-rings in ball retained overdentures deteriorate with time and wish alternative to revive the retentive high quality. We evaluated retrospectively the mechanical properties of o-rings after Three years in perform in one and two-piece implant-supported overdentures. The o-rings have been retrieved from one-piece (Myriad snap, Equinox-Straumann, 3.Three x 13mm) and two-piece (Neo Biotech, 3.Three x 13mm) implant-supported overdenture sufferers.
A complete of 16 pairs of matrices have been examined for put on, kind of injury and elasticity utilizing Pin on Disc methodology, USB Digital Camera in 30x zoom and Universal Tensile Machine respectively. The statistical evaluation for impartial teams have been performed with the Mann-Whitney U take a look at. Assessment of used O-rings confirmed 84% extra put on in the two-piece system with an abrasive kind of injury whereas 46% put on in the one-piece system with a compressive kind of injury.
Global Regulation of Genetically Modified Crops Amid the Gene Edited Crop Boom – A Review
Products derived from agricultural biotechnology is quick turning into one of the largest agricultural commerce commodities globally, clothes us, feeding our livestock, and fueling our eco-friendly automobiles. This exponential progress happens regardless of asynchronous regulatory schemes round the world, starting from moratoriums and prohibitions on genetically modified (GM) organisms, to rules that deal with each typical and biotech novel plant merchandise underneath the identical regulatory framework. Given the monumental floor space being cultivated, there is no such thing as a longer a query of acceptance or outright want for biotech crop varieties. Recent recognition of the researchers for the growth of a genome modifying method utilizing CRISPR/Cas9 by the Nobel Prize committee is one other step nearer to growing and cultivating new varieties of agricultural crops.
By using exact, environment friendly, but inexpensive genome modifying methods, new genome edited crops are getting into nation regulatory schemes for commercialization. Countries which at the moment dominate in cultivating and exporting GM crops are shortly recognizing differing kinds of gene-edited merchandise by evaluating the merchandise to conventionally bred varieties. This nuanced legislative growth, first carried out in Argentina, and shortly adopted by many, exhibits appreciable shifts in the panorama of agricultural biotechnology merchandise. The evolution of the legislation on gene edited crops demonstrates that the legislation just isn’t static and should alter to the mores of society, knowledgeable by the experiences of 25 years of cultivation and regulation of GM crops.
The crux of this evaluate is a consolidation of the international legislative panorama on GM crops, because it stands, constructing on earlier works by particularly addressing how gene edited crops will match into the current frameworks. This work is the first of its type to synthesize the relevant regulatory paperwork throughout the globe, with a deal with GM crop cultivation, and gives hyperlinks to unique laws on GM and gene edited crops. Next, an in depth dialogue of the state of the artwork, and technical challenges and alternatives related to C-MEMS and C-NEMS units used in biotech functions are offered.
Perspectives on C-MEMS and C-NEMS biotech functions
Carbon microelectromechanical system (C-MEMS) and carbon nanoelectromechanical system (C-NEMS) have been recognized as promising applied sciences for a spread of biotech functions, together with electrochemical biosensors, biofuel cells, neural probes, and dielectrophoretic cell trapping. Research groups round the world have devoted increasingly time to this area. After nearly 20 years of efforts on growing C-MEMS and C-NEMS, a evaluate of the related progress and addressing future analysis alternatives and demanding points is in order. This evaluate first introduces C-MEMS and C-NEMS fabrication processes that fall into two classes: photolithography- and non-photolithography- primarily based methods.
Recombinant (E.Coli) Anti-Tetanus Toxoid scFv IgG |
RP-343 |
Alpha Diagnostics |
10 ug |
EUR 343.2 |
Anti-ROR1 (clone R11) scFv-Fc-Sec ADC |
ADC-W-434 |
Creative Biolabs |
1mg |
Ask for price |
Description: This ADC product is comprised of an anti-ROR1 scFv-Fc (clone R11) conjugated via a engineered selenocysteine (Sec) residue linker to a drug |
Anti-COVID-19 Nucleocapsid Protein scFv Antibody |
E38A9964 |
EnoGene |
100ug/100ul |
EUR 225 |
Description: Available in various conjugation types. |
Biotinylated FMC63 scFv, Fc,Avitag™ (MALS verified) |
CD9-BV4324b |
ACROBIOSYSTEMS |
25ug |
EUR 1294.7 |
|
Description: Biotinylated FMC63 scFv, Fc, Avitag is a chimeric monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. |
E.coli anti-COVID-19 Nucleocapsid Protein scFv Antibody |
DL99719A-100ul |
DL Develop |
100 ul |
EUR 299 |
|
Description: Nucleoprotein; Nucleocapsid protein; NC; Protein N |
E.coli anti-COVID-19 Nucleocapsid Protein scFv Antibody |
DL99719A-50ul |
DL Develop |
50 ul |
EUR 210 |
|
Description: Nucleoprotein; Nucleocapsid protein; NC; Protein N |
Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ) |
78600 |
BPS Bioscience |
50 µl |
EUR 1150 |
Description: The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. These viruses constitutively express the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge, 4-1BB, and CD3ζ signaling domains. |
Recombinant Anti-CD3 x Anti-CEA Bispecific Antibody (Tandem scFv) |
BSFV-072-100ug |
Creative Biolabs |
100μg |
EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-CEA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colorectal cancer (CRC); Breast cancer; Lung cancer; Gastric cancer therapy. |
Recombinant Anti-CD3 x Anti-CEA Bispecific Antibody (Tandem scFv) |
BSFV-072-50ug |
Creative Biolabs |
50μg |
EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-CEA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colorectal cancer (CRC); Breast cancer; Lung cancer; Gastric cancer therapy. |
Recombinant Anti-FIXa x Anti-FX Bispecific Antibody (Tandem scFv) |
BSFV-162-100ug |
Creative Biolabs |
100μg |
EUR 4552.8 |
Description: A bispecific antibody that is expressed as an anti-FIXa scFv fused with an anti-FX scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can bind and dimerize two factors. It acts as mimetic FXIII. It is designed for the research of Hemophilia A therapy. |
Recombinant Anti-FIXa x Anti-FX Bispecific Antibody (Tandem scFv) |
BSFV-162-50ug |
Creative Biolabs |
50μg |
EUR 2587.2 |
Description: A bispecific antibody that is expressed as an anti-FIXa scFv fused with an anti-FX scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can bind and dimerize two factors. It acts as mimetic FXIII. It is designed for the research of Hemophilia A therapy. |
Recombinant Anti-BSA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-c001-100ug |
Creative Biolabs |
100μg |
EUR 4552.8 |
Description: A bispecific antibody that is expressed as an anti-BSA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can be used as a negative control to other anti-CD3 BsAbs in the research of tumor therapy. |
Recombinant Anti-BSA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-c001-50ug |
Creative Biolabs |
50μg |
EUR 2587.2 |
Description: A bispecific antibody that is expressed as an anti-BSA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can be used as a negative control to other anti-CD3 BsAbs in the research of tumor therapy. |
Recombinant Anti-BCMA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-020-100ug |
Creative Biolabs |
100μg |
EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-BCMA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Multiple myeloma (MM) therapy. |
Recombinant Anti-BCMA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-020-50ug |
Creative Biolabs |
50μg |
EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-BCMA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Multiple myeloma (MM) therapy. |
Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-030-100ug |
Creative Biolabs |
100μg |
EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-CD123 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy. |
Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-030-50ug |
Creative Biolabs |
50μg |
EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-CD123 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy. |
Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-041-100ug |
Creative Biolabs |
100μg |
EUR 4552.8 |
Description: A bispecific antibody that is expressed as an anti-CD19 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy. |
Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-041-50ug |
Creative Biolabs |
50μg |
EUR 2587.2 |
Description: A bispecific antibody that is expressed as an anti-CD19 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy. |
Recombinant Anti-CD2 x Anti-EGFR Bispecific Antibody (Tandem scFv) |
BSFV-046-100ug |
Creative Biolabs |
100μg |
EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-CD2 scFv fused with an anti-EGFR scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
Recombinant Anti-CD2 x Anti-EGFR Bispecific Antibody (Tandem scFv) |
BSFV-046-50ug |
Creative Biolabs |
50μg |
EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-CD2 scFv fused with an anti-EGFR scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
Recombinant Anti-CD33 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-066-100ug |
Creative Biolabs |
100μg |
EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-CD33 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy. |
Recombinant Anti-CD33 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-066-50ug |
Creative Biolabs |
50μg |
EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-CD33 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy. |
Recombinant Anti-EGFR x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-077-100ug |
Creative Biolabs |
100μg |
EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-EGFR scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
Recombinant Anti-EGFR x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-077-50ug |
Creative Biolabs |
50μg |
EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-EGFR scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
Recombinant Anti-EPCAM x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-079-100ug |
Creative Biolabs |
100μg |
EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-EPCAM scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy. |
Recombinant Anti-EPCAM x Anti-CD3 Bispecific Antibody (Tandem scFv) |
BSFV-079-50ug |
Creative Biolabs |
50μg |
EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-EPCAM scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy. |
Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (Tandem scFv) |
BSFV-102-100ug |
Creative Biolabs |
100μg |
EUR 4272 |
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-PSMA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy. |
Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (Tandem scFv) |
BSFV-102-50ug |
Creative Biolabs |
50μg |
EUR 2446.8 |
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-PSMA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy. |
Anti-Amyloid Beta Reference Antibody (CSIRO anti-amyloid Beta scFv) |
E24CHA691 |
EnoGene |
100 μg |
EUR 225 |
Description: Available in various conjugation types. |
Anti-CD22 CAR Lentivirus (Clone m971 ScFv-CD8-4-1BB-CD3ζ) |
78608 |
BPS Bioscience |
50 µl |
EUR 1095 |
Description: The anti-CD22 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD22 (clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (below). |
Anti-BCMA CAR Lentivirus (Clone C11D5.3 ScFv-CD8-4-1BB-CD3ζ) |
78655 |
BPS Bioscience |
50 µl |
EUR 1095 |
Description: The anti-BCMA CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-BCMA (clone C11D5.3) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1). The lentiviruses also transduce a puromycin selection gene. |
GC Control |
A23 |
DataApex |
- |
EUR 600 |
Description: SW module for GC control |
LC Control |
A24 |
DataApex |
- |
EUR 600 |
Description: SW module for HPLC/CE control (pump, det, etc.) |
AS Control |
A26 |
DataApex |
- |
EUR 330 |
Description: SW module for AS control |
Rat neurofascin (Nfasc)-control Control/blocking peptide |
AB-23249-CP |
Alpha Diagnostics |
100ug |
EUR 196.8 |
Anti-CD20 CAR Lentivirus (Clone Leu-16 ScFv-CD8-4-1BB-CD3ζ) |
78606 |
BPS Bioscience |
50 µl |
EUR 1095 |
Description: The anti-CD20 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD20 (clone Leu-16) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains . |
Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector) |
78601 |
BPS Bioscience |
50 µl |
EUR 1150 |
Description: The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, 4-1BB and CD3ζ signaling domains .Note: This product transduces the same construct as the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ) (BPS Bioscience #78600), but differs in key aspects:78601 is constructed with a SIN lentivector while 78600 is not. 78601 does not contain an antibiotic for selection while 78600 contains a puromycin selection so the transduced cells can be selected with puromycin. |
Rat IgG-PE conjugate (isotype control) (Isotype control) |
20005-PE |
Alpha Diagnostics |
25 tests |
EUR 242.4 |
Dengue Control |
ant-543 |
ProSpec Tany |
100µg |
EUR 165 |
Description: Mouse Anti-Dengue Control for Lateral Flow Test |
Rat IgG-HRP conjugate (isotype control) (Isotype control) |
20005-HP |
Alpha Diagnostics |
100 ug |
EUR 196.8 |
Rat IgG-FITC conjugate (isotype control) (Isotype control) |
20005-F |
Alpha Diagnostics |
100 ug |
EUR 196.8 |
Quality Control |
abx098966-1vial |
Abbexa |
1 vial |
EUR 360 |
|
Rat IgG-Biotin conjugate (isotype control) (Isotype control) |
20005-B |
Alpha Diagnostics |
100 ug |
EUR 196.8 |
PIPET CONTROLLER CONTROL BOARD |
357484 |
CORNING |
1/pk |
EUR 104.4 |
Description: Falcon Liquid Handling Equipment; Falcon Pipet Controllers and Accessories |
Goat IgG (-ve control for flow cytometry) (isotype control) |
20011-100 |
Alpha Diagnostics |
100 test |
EUR 123.6 |
Control siRNA Vector (pGB-control) |
9500C-20 |
Biovision |
each |
EUR 405.6 |
OOSA10387-100T - IgM NEGATIVE CONTROL Negative/Isotype Control |
OOSA10387-100T |
Aviva Systems Biology |
100Tests |
EUR 309 |
|
OOSA10342-100UG - IgG1 NEGATIVE CONTROL Negative/Isotype Control |
OOSA10342-100UG |
Aviva Systems Biology |
0.1mg |
EUR 219 |
|
OOSA10349-100T - IgG2a NEGATIVE CONTROL Negative/Isotype Control |
OOSA10349-100T |
Aviva Systems Biology |
100Tests |
EUR 299 |
|
OOSA10380-100T - IgG2b NEGATIVE CONTROL Negative/Isotype Control |
OOSA10380-100T |
Aviva Systems Biology |
100Tests |
EUR 309 |
|
OOSA10389-100T - IgG1 NEGATIVE CONTROL Negative/Isotype Control |
OOSA10389-100T |
Aviva Systems Biology |
100Tests |
EUR 309 |
|
OOSA10397-100T - IgG2a NEGATIVE CONTROL Negative/Isotype Control |
OOSA10397-100T |
Aviva Systems Biology |
100Tests |
EUR 309 |
|
Rat Control IgG |
AC034 |
Abclonal |
100 ul |
EUR 159.6 |
β-Gal Control |
LV007 |
ABM |
4 x 500 ul |
EUR 195 |
Goat IgG control |
31R-AG001 |
Fitzgerald |
1 mg |
EUR 152.4 |
Description: Goat Immunoglobulins Goat IgG control |
Goat IgG Control |
GT15900 |
Neuromics |
1 mg |
EUR 199.2 |
MG-BSA Control |
STA-306 |
Cell Biolabs |
100 µg |
EUR 386.4 |
Description: - Methylglyoxal-BSA (MG-BSA) may be used as a positive control. 100 µg at 1 mg/mL in PBS.
- Provided at 1 mg/mL
|
Mouse IgG Control |
10R-I169A |
Fitzgerald |
250 ug |
EUR 152.4 |
Description: Mouse Immunoglobulins Mouse IgG Control |
Mouse Control IgG |
AC011 |
Abclonal |
100 ul |
EUR 159.6 |
Mouse IgM Control |
ICIGMF-100 |
ImmunoStep |
100 µg |
EUR 239.4 |
Mouse IgM Control |
ICIGMPU-100 |
ImmunoStep |
100 µg |
EUR 239.4 |
CEL-BSA Control |
STA-302 |
Cell Biolabs |
100 µg |
EUR 386.4 |
Description: - N-epsilon-(carboxyethyl) lysine (CEL) modified BSA may be used as a positive control. 100 µg at 1 mg/mL in PBS.
- Provided at 1 mg/mL in 1X PBS
|
CML-BSA Control |
STA-314 |
Cell Biolabs |
100 µg |
EUR 386.4 |
Description: - CML-BSA may be used as a positive control. 100 µg.
- Provided at 1 mg/mL in 1X PBS
|
MDA-BSA Control |
STA-333 |
Cell Biolabs |
100 µg |
EUR 386.4 |
Description: - MDA-BSA (Malondialdehyde-BSA) may be used as a positive control. 100 µg.
- Provided at 1 mg/mL in 1X PBS
|
HNE-BSA Control |
STA-335 |
Cell Biolabs |
100 µg |
EUR 386.4 |
Description: - HNE-BSA (4-Hydroxynonenal-BSA) may be used as a positive control. 100 µg.
- Provided at 1 mg/mL in 1X PBS
|
human IgM control |
E4A11C04 |
EnoGene |
50ug |
EUR 255 |
Description: Available in various conjugation types. |
human IgE control |
E4A11C05 |
EnoGene |
50ug |
EUR 255 |
Description: Available in various conjugation types. |
OOSA10361-1ML - Rat IgG2a NEGATIVE CONTROL Negative/Isotype Control |
OOSA10361-1ML |
Aviva Systems Biology |
1ml |
EUR 169 |
|
Rabbit Control IgG |
AC005 |
Abclonal |
100 ul |
EUR 159.6 |
Rabbit IgG Control |
31R-AR001 |
Fitzgerald |
500 ug |
EUR 159.6 |
Description: Purified Normal Rabbit IgG |
Mouse IgG1 Control |
ICIGG1A-50 |
ImmunoStep |
50 µg |
EUR 387.6 |
Mouse IgG1 Control |
ICIGG1AC750-50 |
ImmunoStep |
50 µg |
EUR 855.6 |
Mouse IgG1 Control |
ICIGG1CFB-100 |
ImmunoStep |
100 µg |
EUR 387.6 |
Mouse IgG1 Control |
ICIGG1F-100 |
ImmunoStep |
100 µg |
EUR 239.4 |
Mouse IgG1 Control |
ICIGG1PE-50 |
ImmunoStep |
50 µg |
EUR 387.6 |
Mouse IgG1 Control |
ICIGG1PP-100 |
ImmunoStep |
100 µg |
EUR 387.6 |
Mouse IgG1 Control |
ICIGG1PP5.5-100 |
ImmunoStep |
100 µg |
EUR 387.6 |
Mouse IgG1 Control |
ICIGG1PU-100 |
ImmunoStep |
100 µg |
EUR 239.4 |
Mouse IgG3 Control |
ICIGG3A-50 |
ImmunoStep |
100 µg |
EUR 777.6 |
Mouse IgG3 Control |
ICIGG3CFB-100 |
ImmunoStep |
100 µg |
EUR 465.6 |
Mouse IgG3 Control |
ICIGG3F-100 |
ImmunoStep |
100 µg |
EUR 387.6 |
Mouse IgG3 Control |
ICIGG3PE-50 |
ImmunoStep |
50 µg |
EUR 621.6 |
Mouse IgG3 Control |
ICIGG3PU-100 |
ImmunoStep |
100 µg |
EUR 387.6 |
human IgG1 control |
E4A11C03 |
EnoGene |
50ug |
EUR 255 |
Description: Available in various conjugation types. |
These units are mentioned in the related sub-sections of biosensors, biofuel cells, intracorporeal neural probe, dielectrophoresis cell trapping, and cell tradition. The evaluate concludes with an exposition of future views in C-MEMS and C-NEMS. The o-rings in one-piece system confirmed enhance in elongation and most displacement to 2% and seven% respectively, whereas two-piece system confirmed lower in elongation and most displacement by 13% and 6% respectively. In one-piece system, the loss of retention was extra with gradual put on fee and in two-piece system, the put on resistance of O-rings decreased as a consequence of elevated stiffness. Further research to guage the adjustments in O-ring with elevated pattern dimension and at interval 1 yr will pave approach for perception into the progressive adjustments in the mechanical properties of an O-ring.